Chronic Myelomonocytic Leukemia Clinical Trials

262 clinical trials for Chronic Myelomonocytic Leukemia across international registries, including 48 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS — RECRUITING · PHASE2
• Pacritinib in CMML — RECRUITING · PHASE1
• Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome — RECRUITING · PHASE2
• Personalized NK Cell Therapy in CBT — RECRUITING · PHASE2
• A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose) — RECRUITING · PHASE2
• Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer — RECRUITING · PHASE2
• Phase I/II Clinical Trial of Axatilimab, a CSF1R Monoclonal Antibody, in Combination With Ruxolitinib as Therapy for Patients With Myelofibrosis (MF) and Chronic Myelomonocytic Leukemia (CMML) — RECRUITING · PHASE1
• A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia. — RECRUITING · PHASE2
• Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning — RECRUITING · PHASE2
• Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. — RECRUITING · PHASE1
• 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia — RECRUITING · PHASE1
• 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome — RECRUITING · PHASE1
• Study to Evaluate the Safety and Tolerability of EP0042 — RECRUITING · PHASE1
• Relevance of Peripheral Cells in the Pathophysiology of Chronic Myelomonocytic Leukemia (CMML) — RECRUITING
• Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant — RECRUITING · PHASE1
• Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies — RECRUITING · PHASE2
• Thiotepa-Containing Conditioning Regimen for Allogeneic HSCT in Chronic Myelomonocytic Leukemia — RECRUITING · NA
• A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia — RECRUITING · PHASE2
• HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant — RECRUITING · PHASE1
• Methods of T Cell Depletion Trial (MoTD) — RECRUITING · PHASE2
• A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) — RECRUITING · PHASE2
• Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia — RECRUITING · PHASE2
• Biological, Prospective Study Evaluating the Dosage of Plasma Cytokines Including the FLT3 Ligand and IL6 of Patients Treated With Non-intensive Chemotherapy — RECRUITING
• Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia — RECRUITING · PHASE1
• Combined Evaluation of Epigenetic and Sensitising Therapy in AML and MDS — RECRUITING · PHASE1
• A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation — RECRUITING · PHASE2
• A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias — RECRUITING · PHASE1
• Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia — RECRUITING · PHASE1
• Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant — RECRUITING · PHASE1
• Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation — RECRUITING · PHASE2
• A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) — RECRUITING · PHASE1
• Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML — RECRUITING · PHASE2
• Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation — RECRUITING · PHASE2
• IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2) — RECRUITING · PHASE3
• Two Step Haplo With Radiation Conditioning — RECRUITING · PHASE2
• Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia — RECRUITING · PHASE1
• Oral-ATO for TP53-mutated Myeloid Malignancies — RECRUITING · PHASE2
• ABBA CORD: dCBT w/ Abatacept for aGVHD Prophylaxis — RECRUITING · PHASE2
• Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial — RECRUITING · PHASE2
• Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies — RECRUITING · PHASE1
• Intensive Conditioning withTHI/Bu/Flu/Ara-C in Allo-HSCT for Myeloid Malignancies With Extramedullary Involvement — RECRUITING
• Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition — RECRUITING · PHASE1
• Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML — RECRUITING · PHASE1
• Combining Active and Passive DNA Hypomethylation — RECRUITING · PHASE2
• PROTOCOL 10538, VENETOCLAX IN COMBINATION WITH ASTX727, AN ALL-ORAL THERAPY FOR CHRONIC MYELOMONOCYTIC LEUKEMIA AND OTHER MDS/MPN WITH EXCESS BLASTS (VICTORY-MDS/MPN): A RANDOMIZED, PHASE 2 TRIAL — RECRUITING · PHASE2
• A MULTIPHASE, PHARMACOKINETICS, SAFETY, AND EFFICACY STUDY OF ASTX030 (AZACITIDINE AND CEDAZURIDINE) AS MONOTHERAPY IN SUBJECTS WITH MYELOID NEOPLASM OR IN COMBINATION WITH VENETOCLAX IN SUBJECTS WITH AML (AZTOUND STUDY) — RECRUITING
• PHASE 1B/2 OPEN-LABEL, MULTICENTER, DOSE OPTIMIZATION CLINICAL STUDY OF THE SAFETY, TOLERABILITY, AND PHARMACOKINETIC AND PHARMACODYNAMIC PROFILES OF CFI 400945 AS A SINGLE AGENT OR IN COMBINATION WITH AZACITIDINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA, MYELODYSPLASTIC SYNDROME OR CHRONIC MYELOMONOCYTIC LEUKEMIA — RECRUITING · PHASE1
• A PHASE 3, RANDOMIZED, CONTROLLED, OPEN-LABEL, CLINICAL STUDY OF PEVONEDISTAT PLUS AZACITIDINE VERSUS SINGLE-AGENT AZACITIDINE AS FIRST-LINE TREATMENT FOR PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROMES, CHRONIC MYELOMONOCYTIC LEUKEMIA, OR LOW-BLAST ACUTE MYELOGENOUS LEUKEMIA — RECRUITING · PHASE3
• A Phase I/II Study of Lenalidomide in Patients with Chronic Myelomonocytic Leukemia — COMPLETED · PHASE2
• Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia — ACTIVE_NOT_RECRUITING · PHASE1

Refine this search